Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Katlin Fendler"'
Autor:
Kelsey Sokol, Kelley Yuan, Maria Piddoubny, Ellen Sweeney, Anne Delengowski, Katlin Fendler, Gloria Espinosa, Judith Alberto, Patricia Galanis, Carol Gung, Meghan Stokley, Mercy George, Mary Harris, Ubaldo Martinez-Outschoorn, Onder Alpdogan, Pierluigi Porcu, Adam F. Binder
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
IntroductionMethotrexate (MTX) a folate antagonist is often given in high doses (≥500 mg/m2) to treat a variety of disease processes. While inpatient administration has been the norm, outpatient administration, has been shown to be safe, effective,
Externí odkaz:
https://doaj.org/article/6757f7c738b94c7aa3e79f378ee28e54
Autor:
Katlin Fendler, Gloria Espinosa, Judith Alberto, Dianne Morales, Megan Miraglia, Adam F Binder
Publikováno v:
Journal of Clinical Oncology. 40:260-260
260 Background: Patients with hematologic malignancies are often electively admitted for chemotherapy. Through an informal survey, patients expressed the desire to start chemotherapy within 4 hours of arriving to the hospital. Not only is this an imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17e7c6475fe14add29afe717f70b443f
https://doi.org/10.1200/jco.2022.40.28_suppl.260
https://doi.org/10.1200/jco.2022.40.28_suppl.260
Autor:
Mercy George, Adam Binder, Carol Gung, Katlin Fendler, Ubaldo E. Martinez-Outschoorn, Samantha Burdette, Anne Delengowski, Kelsey Sokol, Maria Piddoubny, Onder Alpdogan, Kelley Yuan, Patricia Galanis, Pierluigi Porcu
Publikováno v:
Journal of Clinical Oncology. 38:30-30
30 Background: High-dose methotrexate (HDMTX) is administered for the treatment of primary central nervous system (CNS) lymphoma (PCNSL), leptomeningeal metastases, and osteosarcoma, as well as CNS prophylaxis in patients with high-risk lymphoma and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f3ab1bb0654db0064de858e65b05486
https://doi.org/10.1200/jco.2020.38.29_suppl.30
https://doi.org/10.1200/jco.2020.38.29_suppl.30